Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Status Terminated

Clinical Trial Summary

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04338061
Study type	Interventional
Source	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Contact
Status	Terminated
Phase	Phase 3
Start date	July 2, 2020
Completion date	March 19, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04121065` - Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
Active, not recruiting	`NCT03996291` - Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis	Phase 2
Recruiting	`NCT04510220` - 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis	Phase 3
Terminated	`NCT02241785` - Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies	Phase 4
Completed	`NCT02792218` - Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis	Phase 3
Completed	`NCT01412333` - A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis	Phase 3
Completed	`NCT03257358` - A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod	Phase 4
Completed	`NCT01628393` - Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients	Phase 2/Phase 3
Completed	`NCT04626921` - A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis	Phase 2/Phase 3
Withdrawn	`NCT02234869` - Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy	Phase 4
Withdrawn	`NCT05077956` - Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
Active, not recruiting	`NCT04486716` - A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis	Phase 3
Recruiting	`NCT04121403` - Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)	Phase 3
Recruiting	`NCT05809986` - Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Terminated	`NCT00988052` - A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course	Phase 3
Active, not recruiting	`NCT05232825` - A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	Phase 3
Terminated	`NCT01047319` - A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis	Phase 3
Completed	`NCT04847596` - A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Completed	`NCT01127750` - Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients	Phase 3
Completed	`NCT01006941` - Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study	Phase 2